2006 Annual Meeting | Mild Cognitive Impairment: Implications for Clinicians

Date Saturday 04/01/06

Time 06:00 PM - 08:00 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Kick-Off Program

Director(s) Ronald C. Petersen, MD, PhD, FAAN

Topic(s)

Learning Objectives Upon Completion:
Participants should be able to diagnose MCI, define the outcome of patients, understand the pathophysiology of the condition, and be aware of treatment options and coding information regarding this diagnosis.

CME Available No CME available

Core Competencies Patient Care & Procedural Skills, Professionalism, Medical Knowledge, Practice-based Learning and Improvement

Program Level Advanced

Recommended Audience Practitioner, Fellow, Academician, Resident, Nurse, Other

Event Timeline
06:00 PM - 06:35 PM		Overview of Mild Cognitive Impairment Ronald C. Petersen, MD, PhD, FAAN
06:00 PM - 08:00 PM		Reception
06:35 PM - 07:05 PM		Neuropathology and Neurochemistry of Mild Cognitive Impairment Steven T. DeKosky, MD, FAAN
07:05 PM - 07:40 PM		Treatment of Mild Cognitive Impairment Leon J. Thal, MD
07:40 PM - 08:00 PM		Questions and Answers

Faculty Disclosures
Ronald C. Petersen, MD, PhD, FAAN	Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly and Co.. Dr. Petersen has received personal compensation in the range of $0-$499 for serving as a Consultant for Eisai, Inc.. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novo Nordisk. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has a non-compensated relationship as a Board of Directors with American Brain Foundation that is relevant to AAN interests or activities.
Steven T. DeKosky, MD, FAAN	Dr. DeKosky has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Acumen. Dr. DeKosky has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. DeKosky has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cognition Therapeutics. Dr. DeKosky has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Prevail Pharamceuticls. Dr. DeKosky has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Vaccinex, Inc. Dr. DeKosky has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Up-To-Date. Dr. DeKosky has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurotherapeutics .
Leon J. Thal, MD	No disclosure on file

��ɫ��

��ɫ��